Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity

Cell Reports

Volumn 15, Issue 2, 2016, Pages 274-287

  Aaes, Tania Løve ^a,b   Kaczmarek, Agnieszka ^a,b   Delvaeye, Tinneke ^a,b   De Craene, Bram ^a,b   De Koker, Stefaan ^b   Heyndrickx, Liesbeth ^a,b   Delrue, Iris ^a,b   Taminau, Joachim ^a,b   Wiernicki, Bartosz ^a,b   De Groote, Philippe ^a,b   Garg, Abhishek D ^c   Leybaert, Luc ^b   Grooten, Johan ^b   Bertrand, Mathieu J M ^a,b   Agostinis, Patrizia ^c   Berx, Geert ^a,b   Declercq, Wim ^a,b   Vandenabeele, Peter ^a,b   Krysko, Dmitri V ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CELL PROTEIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GAMMA INTERFERON; PROTEIN RIPK3; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ALARMIN; ANTINEOPLASTIC AGENT; CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; TETRACYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CANCER PREVENTION; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DIMERIZATION; EX VIVO STUDY; FEMALE; GENETIC MODEL; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NECROPTOSIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR IMMUNITY; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; BONE MARROW CELL; CELL PROLIFERATION; CYTOLOGY; DENDRITIC CELL; DRUG EFFECT; IMMUNITY; IMMUNOLOGY; METABOLISM; NECROSIS; PHAGOCYTOSIS; PROTEIN MULTIMERIZATION; TUMOR CELL LINE; VACCINATION;

ALARMINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINES; CROSS-PRIMING; DENDRITIC CELLS; IMMUNITY; LIGANDS; MICE; MODELS, BIOLOGICAL; NECROSIS; NEOPLASMS; NF-KAPPA B; PHAGOCYTOSIS; PROTEIN MULTIMERIZATION; TETRACYCLINE; VACCINATION;

EID: 84962069613     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.03.037     Document Type: Article

References (45)

1. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
2. Casares N., Pequignot M.O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., Schmitt E., Hamai A., Hervas-Stubbs S., Obeid M., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 2005, 202:1691-1701.
3. Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., Chan F.K. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009, 137:1112-1123.
4. Degterev A., Huang Z., Boyce M., Li Y., Jagtap P., Mizushima N., Cuny G.D., Mitchison T.J., Moskowitz M.A., Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 2005, 1:112-119.
5. Denecker G., Vercammen D., Steemans M., Vanden Berghe T., Brouckaert G., Van Loo G., Zhivotovsky B., Fiers W., Grooten J., Declercq W., Vandenabeele P. Death receptor-induced apoptotic and necrotic cell death: differential role of caspases and mitochondria. Cell Death Differ. 2001, 8:829-840.
6. Dondelinger Y., Aguileta M.A., Goossens V., Dubuisson C., Grootjans S., Dejardin E., Vandenabeele P., Bertrand M.J. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ. 2013, 20:1381-1392.
7. Dynek J.N., Goncharov T., Dueber E.C., Fedorova A.V., Izrael-Tomasevic A., Phu L., Helgason E., Fairbrother W.J., Deshayes K., Kirkpatrick D.S., Vucic D. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 2010, 29:4198-4209.
8. Fulda S. Therapeutic exploitation of necroptosis for cancer therapy. Semin. Cell Dev. Biol. 2014, 35:51-56.
9. Garg A.D., Krysko D.V., Vandenabeele P., Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol. Immunother. 2012, 61:215-221.
10. Garg A.D., Krysko D.V., Verfaillie T., Kaczmarek A., Ferreira G.B., Marysael T., Rubio N., Firczuk M., Mathieu C., Roebroek A.J., et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012, 31:1062-1079.
11. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
12. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
13. He S., Wang L., Miao L., Wang T., Du F., Zhao L., Wang X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009, 137:1100-1111.
14. He L., Peng K., Liu Y., Xiong J., Zhu F.F. Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients. Onco Targets Ther. 2013, 6:1539-1543.
15. Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., Bodmer J.L., Schneider P., Seed B., Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 2000, 1:489-495.
16. Huang A.Y.C., Gulden P.H., Woods A.S., Thomas M.C., Tong C.D., Wang W., Engelhard V.H., Pasternack G., Cotter R., Hunt D., et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 1996, 93:9730-9735.
17. Jinushi M., Hodi F.S., Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol. Rev. 2008, 222:287-298.
18. Kaczmarek A., Vandenabeele P., Krysko D.V. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013, 38:209-223.
19. Kang T.B., Yang S.H., Toth B., Kovalenko A., Wallach D. Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 2013, 38:27-40.
20. Kepp O., Senovilla L., Vitale I., Vacchelli E., Adjemian S., Agostinis P., Apetoh L., Aranda F., Barnaba V., Bloy N., et al. Consensus guidelines for the detection of immunogenic cell death. OncoImmunology 2014, 3:e955691.
21. Koo G.B., Morgan M.J., Lee D.G., Kim W.J., Yoon J.H., Koo J.S., Kim S.I., Kim S.J., Son M.K., Hong S.S., et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015, 25:707-725.
22. Krysko D.V., Denecker G., Festjens N., Gabriels S., Parthoens E., D'Herde K., Vandenabeele P. Macrophages use different internalization mechanisms to clear apoptotic and necrotic cells. Cell Death Differ. 2006, 13:2011-2022.
23. Krysko D.V., Garg A.D., Kaczmarek A., Krysko O., Agostinis P., Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 2012, 12:860-875.
24. Li J., McQuade T., Siemer A.B., Napetschnig J., Moriwaki K., Hsiao Y.S., Damko E., Moquin D., Walz T., McDermott A., et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 2012, 150:339-350.
25. Lohmann C., Muschaweckh A., Kirschnek S., Jennen L., Wagner H., Häcker G. Induction of tumor cell apoptosis or necrosis by conditional expression of cell death proteins: analysis of cell death pathways and in vitro immune stimulatory potential. J. Immunol. 2009, 182:4538-4546.
26. Ma Y., Adjemian S., Mattarollo S.R., Yamazaki T., Aymeric L., Yang H., Portela Catani J.P., Hannani D., Duret H., Steegh K., et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013, 38:729-741.
27. Majno G., Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 1995, 146:3-15.
28. Michaud M., Martins I., Sukkurwala A.Q., Adjemian S., Ma Y., Pellegatti P., Shen S., Kepp O., Scoazec M., Mignot G., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
29. Murphy J.M., Czabotar P.E., Hildebrand J.M., Lucet I.S., Zhang J.G., Alvarez-Diaz S., Lewis R., Lalaoui N., Metcalf D., Webb A.I., et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013, 39:443-453.
30. Nugues A.L., El Bouazzati H., Hétuin D., Berthon C., Loyens A., Bertrand E., Jouy N., Idziorek T., Quesnel B. RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. Cell Death Dis. 2014, 5:e1384.
31. Obeid M., Panaretakis T., Joza N., Tufi R., Tesniere A., van Endert P., Zitvogel L., Kroemer G. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007, 14:1848-1850.
32. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
33. Panaretakis T., Kepp O., Brockmeier U., Tesniere A., Bjorklund A.C., Chapman D.C., Durchschlag M., Joza N., Pierron G., van Endert P., et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009, 28:578-590.
34. Pasparakis M., Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015, 517:311-320.
35. Pierdomenico M., Negroni A., Stronati L., Vitali R., Prete E., Bertin J., Gough P.J., Aloi M., Cucchiara S. Necroptosis is active in children with inflammatory bowel disease and contributes to heighten intestinal inflammation. Am. J. Gastroenterol. 2014, 109:279-287.
36. Remijsen Q., Goossens V., Grootjans S., Van den Haute C., Vanlangenakker N., Dondelinger Y., Roelandt R., Bruggeman I., Goncalves A., Bertrand M.J., et al. Depletion of RIPK3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis. Cell Death Dis. 2014, 5:e1004.
37. Sun L., Wang H., Wang Z., He S., Chen S., Liao D., Wang L., Yan J., Liu W., Lei X., Wang X. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012, 148:213-227.
38. Takemura R., Takaki H., Okada S., Shime H., Akazawa T., Oshiumi H., Matsumoto M., Teshima T., Seya T. PolyI:C-induced, TLR3/RIP3-dependent necroptosis backs up immune effector-mediated tumor elimination in vivo. Cancer Immunol. Res. 2015, 3:902-914.
39. Vanden Berghe T., van Loo G., Saelens X., Van Gurp M., Brouckaert G., Kalai M., Declercq W., Vandenabeele P. Differential signaling to apoptotic and necrotic cell death by Fas-associated death domain protein FADD. J. Biol. Chem. 2004, 279:7925-7933.
40. Vanlangenakker N., Vanden Berghe T., Bogaert P., Laukens B., Zobel K., Deshayes K., Vucic D., Fulda S., Vandenabeele P., Bertrand M.J. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 2011, 18:656-665.
41. Vince J.E., Wong W.W., Gentle I., Lawlor K.E., Allam R., O'Reilly L., Mason K., Gross O., Ma S., Guarda G., et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 2012, 36:215-227.
42. Wang H., Sun L., Su L., Rizo J., Liu L., Wang L.F., Wang F.S., Wang X. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol. Cell 2014, 54:133-146.
43. Yamazaki T., Hannani D., Poirier-Colame V., Ladoire S., Locher C., Sistigu A., Prada N., Adjemian S., Catani J.P., Freudenberg M., et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2014, 21:69-78.
44. + T cells. Science 2015, 350:328-334.
45. Zhang D.W., Shao J., Lin J., Zhang N., Lu B.J., Lin S.C., Dong M.Q., Han J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009, 325:332-336.